Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

DELIVER (JACCRO GC-08) trial: discover novel host-related immune-biomarkers for nivolumab in advanced gastric cancer.

Sunakawa Y, Inoue E, Matoba R, Kawakami H, Sato Y, Nakajima TE, Muro K, Ichikawa W, Fujii M.

Future Oncol. 2019 Jul;15(21):2441-2447. doi: 10.2217/fon-2019-0167. Epub 2019 May 29.

PMID:
31140303
2.

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.

Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, Nagao N, Takahashi M, Takagane A, Watanabe T, Kaji M, Okitsu H, Nomura T, Matsui T, Yoshikawa T, Matsuyama J, Yamada M, Ito S, Takeuchi M, Fujii M.

J Clin Oncol. 2019 May 20;37(15):1296-1304. doi: 10.1200/JCO.18.01138. Epub 2019 Mar 29.

PMID:
30925125
3.

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors.

Sunakawa Y, Satake H, Ichikawa W.

World J Gastrointest Oncol. 2018 Dec 15;10(12):528-531. doi: 10.4251/wjgo.v10.i12.528.

4.

Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer.

Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W.

Mol Cancer Ther. 2018 Dec;17(12):2788-2795. doi: 10.1158/1535-7163.MCT-18-0694. Epub 2018 Oct 1.

PMID:
30275242
5.

Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C, Tsuji A, Takahashi T, Tanioka H, Negoro Y, Takagane A, Tani S, Yamaguchi T, Eto T, Fujii M, Ichikawa W, Lenz HJ.

Clin Colorectal Cancer. 2018 Dec;17(4):e741-e749. doi: 10.1016/j.clcc.2018.08.002. Epub 2018 Aug 23.

PMID:
30219280
6.

Correction: A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T.

Oncotarget. 2018 Jul 6;9(52):30023. doi: 10.18632/oncotarget.25775. eCollection 2018 Jul 6.

7.

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.

Satake H, Sunakawa Y, Miyamoto Y, Nakamura M, Nakayama H, Shiozawa M, Makiyama A, Kobayashi K, Kubota Y, Mori M, Kotaka M, Takagane A, Gotoh M, Takeuchi M, Fujii M, Ichikawa W, Sekikawa T.

Oncotarget. 2018 Apr 10;9(27):18811-18820. doi: 10.18632/oncotarget.24702. eCollection 2018 Apr 10. Erratum in: Oncotarget. 2018 Jul 6;9(52):30023. Ichikawa, Wararu [corrected to Ichikawa, Wataru].

8.

CEA Response and Depth of Response (DpR) to Predict Clinical Outcomes of First-Line Cetuximab Treatment for Metastatic Colorectal Cancer.

Sunakawa Y, Tsuji A, Denda T, Segawa Y, Negoro Y, Shimada K, Kochi M, Nakamura M, Kotaka M, Tanioka H, Takagane A, Tani S, Yamaguchi T, Watanabe T, Takeuchi M, Fujii M, Ichikawa W.

Target Oncol. 2017 Dec;12(6):787-794. doi: 10.1007/s11523-017-0527-0.

PMID:
29064002
9.

TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study.

Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M; ACTS-GC Group.

Oncotarget. 2017 Mar 4;8(34):57574-57582. doi: 10.18632/oncotarget.15895. eCollection 2017 Aug 22.

10.

A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.

Ueno M, Li CP, Ikeda M, Ishii H, Mizuno N, Yamaguchi T, Ioka T, Oh DY, Ichikawa W, Okusaka T, Matsuyama Y, Arai D, Chen LT, Park YS, Furuse J.

Cancer Chemother Pharmacol. 2017 Aug;80(2):307-315. doi: 10.1007/s00280-017-3351-4. Epub 2017 Jun 20.

11.

Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.

Okazaki S, Stintzing S, Sunakawa Y, Cao S, Zhang W, Yang D, Ning Y, Matsusaka S, Berger MD, Miyamoto Y, Suenaga M, Schirripa M, West JD, Gopez R, Akihito T, Ichikawa W, Heinemann V, DePaolo RW, Lenz HJ.

Int J Cancer. 2017 Sep 15;141(6):1222-1230. doi: 10.1002/ijc.30810. Epub 2017 Jun 21.

12.

Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis.

Furuse J, Gemma A, Ichikawa W, Okusaka T, Seki A, Ishii T.

Jpn J Clin Oncol. 2017 Sep 1;47(9):832-839. doi: 10.1093/jjco/hyx075.

13.

No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?

Sunakawa Y, Tsuji A, Fujii M, Ichikawa W.

Ann Oncol. 2017 Aug 1;28(8):2030-2031. doi: 10.1093/annonc/mdx231. No abstract available.

PMID:
28475674
14.

Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.

Sunakawa Y, Ichikawa W, Tsuji A, Denda T, Segawa Y, Negoro Y, Shimada K, Kochi M, Nakamura M, Kotaka M, Tanioka H, Takagane A, Tani S, Yamaguchi T, Watanabe T, Takeuchi M, Fujii M, Nakajima T.

Clin Colorectal Cancer. 2017 Sep;16(3):e171-e180. doi: 10.1016/j.clcc.2016.09.010. Epub 2016 Oct 6.

PMID:
27856123
15.

Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan.

Takata K, Fujita KI, Kubota Y, Ishida H, Ichikawa W, Shimada K, Sekikawa T, Taki-Takemoto I, Kamei D, Iwai S, Sasaki Y.

J Pharm Health Care Sci. 2016 Nov 9;2:30. eCollection 2016.

16.

The risk of adverse events of CPT- 11.

Imataka H, Sekikawa T, Ichikawa W.

Nihon Rinsho. 2016 Nov;74(11):1847-1851. Japanese.

PMID:
30550693
17.

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials.

Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ.

Pharmacogenomics J. 2018 Jan;18(1):43-48. doi: 10.1038/tpj.2016.69. Epub 2016 Oct 4.

18.

Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX.

Kaga Y, Sunakawa Y, Kubota Y, Tagawa T, Yamamoto T, Ikusue T, Uto Y, Miyashita K, Toshima H, Kobayashi K, Hisamatsu A, Ichikawa W, Sekikawa T, Shimada K, Sasaki Y.

Oncotarget. 2016 Oct 11;7(41):67314-67320. doi: 10.18632/oncotarget.12007.

19.

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.

Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ.

Pharmacogenomics J. 2017 Dec;17(6):543-550. doi: 10.1038/tpj.2016.59. Epub 2016 Aug 9.

PMID:
27503580
20.

A comparison of four methods for detecting KRAS mutations in formalin-fixed specimens from metastatic colorectal cancer patients.

Matsunaga M, Kaneta T, Miwa K, Ichikawa W, Fujita KI, Nagashima F, Furuse J, Kage M, Akagi Y, Sasaki Y.

Oncol Lett. 2016 Jul;12(1):150-156. Epub 2016 May 16.

21.

Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).

Tsuji A, Sunakawa Y, Ichikawa W, Nakamura M, Kochi M, Denda T, Yamaguchi T, Shimada K, Takagane A, Tani S, Kotaka M, Kuramochi H, Furushima K, Koike J, Yonemura Y, Takeuchi M, Fujii M, Nakajima T.

Target Oncol. 2016 Dec;11(6):799-806.

PMID:
27306648
22.

Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.

Sunakawa Y, Yang D, Moran M, Astrow SH, Tsuji A, Stephens C, Zhang W, Cao S, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Masuishi T, Takeuchi M, Fujii M, Nakajima T, Ichikawa W, Lenz HJ.

Cancer Biol Ther. 2016 Jul 2;17(7):751-9. doi: 10.1080/15384047.2016.1178426. Epub 2016 Apr 22.

23.

TWIST1 Polymorphisms Predict Survival in Patients with Metastatic Colorectal Cancer Receiving First-Line Bevacizumab plus Oxaliplatin-Based Chemotherapy.

Matsusaka S, Zhang W, Cao S, Hanna DL, Sunakawa Y, Sebio A, Ueno M, Yang D, Ning Y, Parekh A, Okazaki S, Berger MD, Ichikawa W, Mizunuma N, Lenz HJ.

Mol Cancer Ther. 2016 Jun;15(6):1405-11. doi: 10.1158/1535-7163.MCT-15-0751. Epub 2016 Mar 16.

24.

Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.

Ichikawa W, Terashima M, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M.

Gastric Cancer. 2017 Mar;20(2):263-273. doi: 10.1007/s10120-016-0600-x. Epub 2016 Feb 16.

25.

Crizotinib-induced pancreatic pseudocyst: a novel adverse event.

Ishida H, Ichikawa W, Sasaki Y.

BMJ Case Rep. 2015 Sep 8;2015. pii: bcr2015211556. doi: 10.1136/bcr-2015-211556.

26.

Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?

Sasaki Y, Hamada K, Kaneta T, Takahashi T, Kubota Y, Ishida H, Ichikawa W.

Cancer Sci. 2015 Aug;106(8):1100. doi: 10.1111/cas.12708. No abstract available.

27.

Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).

Tanabe K, Fujii M, Nishikawa K, Kunisaki C, Tsuji A, Matsuhashi N, Takagane A, Ohno T, Kawase T, Kochi M, Yoshida K, Kakeji Y, Ichikawa W, Chin K, Terashima M, Takeuchi M, Nakajima T; JACCRO GC-05 study group.

Ann Oncol. 2015 Sep;26(9):1916-22. doi: 10.1093/annonc/mdv265. Epub 2015 Jun 24.

PMID:
26109630
28.

An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.

Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, Sadahiro S, Fujita K, Moriwaki T, Nakamura M, Takahashi T, Tsuji A, Shinozaki K, Morita S, Ando Y, Okutani Y, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y.

Br J Cancer. 2015 May 12;112(10):1709-16. doi: 10.1038/bjc.2015.122. Epub 2015 Apr 16.

29.

Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer.

Matsuyama M, Ishii H, Furuse J, Ohkawa S, Maguchi H, Mizuno N, Yamaguchi T, Ioka T, Ajiki T, Ikeda M, Hakamada K, Yamamoto M, Yamaue H, Eguchi K, Ichikawa W, Miyazaki M, Ohashi Y, Sasaki Y.

Invest New Drugs. 2015 Apr;33(2):490-5. doi: 10.1007/s10637-014-0197-z. Epub 2014 Dec 13.

30.

Erratum to: Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.

Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H.

Gastric Cancer. 2015 Jul;18(3):549. doi: 10.1007/s10120-014-0428-1. No abstract available.

31.

Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.

Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H.

Gastric Cancer. 2015 Jul;18(3):538-48. doi: 10.1007/s10120-014-0413-8. Epub 2014 Aug 12. Erratum in: Gastric Cancer. 2015 Jul;18(3):549.

32.

ASPECCT: panitumumab versus cetuximab for colorectal cancer.

Sunakawa Y, Ichikawa W, Sasaki Y.

Lancet Oncol. 2014 Jul;15(8):e301-2. doi: 10.1016/S1470-2045(14)70204-9. No abstract available.

PMID:
24988926
33.

MYC interacts with the human STAGA coactivator complex via multivalent contacts with the GCN5 and TRRAP subunits.

Zhang N, Ichikawa W, Faiola F, Lo SY, Liu X, Martinez E.

Biochim Biophys Acta. 2014 May;1839(5):395-405. doi: 10.1016/j.bbagrm.2014.03.017. Epub 2014 Apr 3.

34.

RAS mutations in colorectal cancer.

Sunakawa Y, Lenz HJ, Ichikawa W.

N Engl J Med. 2013 Nov 28;369(22):2159. doi: 10.1056/NEJMc1312697. No abstract available.

PMID:
24283233
35.

Complicated puzzle in cetuximab-based chemotherapy: skin toxicity and resection rate in patients with initially unresectable colorectal liver metastases.

Sunakawa Y, Takahashi T, Ichikawa W, Shimada K, Sasaki Y.

J Clin Oncol. 2013 Dec 10;31(35):4473. doi: 10.1200/JCO.2013.50.8713. Epub 2013 Oct 28. No abstract available.

PMID:
24166514
36.

Study protocol of the B-CAST study: a multicenter, prospective cohort study investigating the tumor biomarkers in adjuvant chemotherapy for stage III colon cancer.

Ishiguro M, Kotake K, Nishimura G, Tomita N, Ichikawa W, Takahashi K, Watanabe T, Furuhata T, Kondo K, Mori M, Kakeji Y, Kanazawa A, Kobayashi M, Okajima M, Hyodo I, Miyakoda K, Sugihara K.

BMC Cancer. 2013 Mar 25;13:149. doi: 10.1186/1471-2407-13-149.

37.

Does a higher response rate to systemic chemotherapy result in a higher resection rate in patients with initially unresectable colorectal liver metastases?

Sunakawa Y, Ichikawa W, Takahashi T, Shimada K, Sasaki Y.

Acta Oncol. 2013 Jun;52(5):1039-40. doi: 10.3109/0284186X.2012.754992. Epub 2013 Jan 17. No abstract available.

PMID:
23327338
38.

[Efficacy assessments for chemotherapy and timing of changing treatment in gastric cancer].

Sunakawa Y, Takahashi T, Sasaki Y, Ichikawa W.

Gan To Kagaku Ryoho. 2012 Sep;39(9):1320-5. Japanese.

PMID:
22996766
39.

Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M; ACTS-GC Group.

Clin Cancer Res. 2012 Nov 1;18(21):5992-6000. doi: 10.1158/1078-0432.CCR-12-1318. Epub 2012 Sep 12.

40.

A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.

Sunakawa Y, Fujita K, Ichikawa W, Ishida H, Yamashita K, Araki K, Miwa K, Kawara K, Akiyama Y, Yamamoto W, Nagashima F, Saji S, Sasaki Y.

Oncology. 2012;82(4):242-8. doi: 10.1159/000337225. Epub 2012 Apr 12.

PMID:
22508373
41.

[Recent advancement in biomarkers to predict the clinical outcome for colorectal cancer patients].

Ichikawa W.

Nihon Rinsho. 2011 Apr;69 Suppl 3:220-5. Review. Japanese. No abstract available.

PMID:
22213961
42.

Phase II study of FOLFOX4 with "wait and go" strategy as first-line treatment for metastatic colorectal cancer.

Kochi M, Ichikawa W, Meguro E, Shibata H, Fukui T, Nagase M, Hoshino Y, Takeuchi M, Fujii M, Nakajima T.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1215-22. doi: 10.1007/s00280-011-1605-0. Epub 2011 Mar 17.

PMID:
21416138
43.

Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.

Ishida H, Fujita K, Akiyama Y, Sunakawa Y, Yamashita K, Mizuno K, Miwa K, Kawara K, Ichikawa W, Ando Y, Saji S, Sasaki Y.

Jpn J Clin Oncol. 2011 May;41(5):617-23. doi: 10.1093/jjco/hyr010. Epub 2011 Feb 9.

PMID:
21310730
44.

Delayed elimination of SN-38 in cancer patients with severe renal failure.

Fujita K, Sunakawa Y, Miwa K, Akiyama Y, Sugiyama M, Kawara K, Ishida H, Yamashita K, Mizuno K, Saji S, Ichikawa W, Yamamoto W, Nagashima F, Miya T, Narabayashi M, Ando Y, Hirose T, Sasaki Y.

Drug Metab Dispos. 2011 Feb;39(2):161-4. doi: 10.1124/dmd.110.035451. Epub 2010 Oct 27.

PMID:
20980446
45.

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.

Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y.

Cancer Chemother Pharmacol. 2011 Aug;68(2):279-84. doi: 10.1007/s00280-010-1485-8. Epub 2010 Oct 19.

PMID:
20957480
46.

[Unique adverse effects of molecular targeted drugs].

Kobayashi T, Ichikawa W.

Nihon Rinsho. 2010 Oct;68(10):1929-35. Review. Japanese.

PMID:
20954342
47.

Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer.

Fujita K, Ando Y, Yamamoto W, Miya T, Endo H, Sunakawa Y, Araki K, Kodama K, Nagashima F, Ichikawa W, Narabayashi M, Akiyama Y, Kawara K, Shiomi M, Ogata H, Iwasa H, Okazaki Y, Hirose T, Sasaki Y.

Cancer Chemother Pharmacol. 2010 Jan;65(2):251-8. doi: 10.1007/s00280-009-1029-2.

PMID:
19466410
48.

Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).

Fujita K, Nakayama H, Ichikawa W, Yamamoto W, Endo H, Nagashima F, Tanaka R, Miya T, Sunakawa Y, Yamashita K, Mizuno K, Ishida H, Araki K, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Hirose T, Sasaki Y.

Drug Metab Dispos. 2009 Jul;37(7):1375-7. doi: 10.1124/dmd.109.027052. Epub 2009 Apr 23.

PMID:
19389859
49.

Fixed dosing and pharmacokinetics of S-1 in Japanese cancer patients with large body surface areas.

Fujita K, Ichikawa W, Yamamoto W, Endo H, Nagashima F, Tanaka R, Miya T, Araki K, Kodama K, Sunakawa Y, Narabayashi M, Miwa K, Ando Y, Akiyama Y, Kawara K, Sasaki Y.

Ann Oncol. 2009 May;20(5):946-9. doi: 10.1093/annonc/mdn718. Epub 2009 Jan 15.

PMID:
19150953
50.

Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).

Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Matsunaga M, Araki K, Tanaka R, Ichikawa W, Miya T, Narabayashi M, Akiyama Y, Kawara K, Ando Y, Sasaki Y.

Biol Pharm Bull. 2008 Nov;31(11):2137-42.

Supplemental Content

Loading ...
Support Center